Integer Holdings (ITGR)
(Delayed Data from NYSE)
$114.49 USD
+1.49 (1.32%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $114.49 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.49 USD
+1.49 (1.32%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $114.49 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Zacks News
CVS Health's PBM Selling Season Strong, Aetna Deal on Track
by Zacks Equity Research
A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.
Amedisys (AMED) Grows on Robust Home Health, Personal Care
by Zacks Equity Research
Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.
ITGR or LMNX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. LMNX: Which Stock Is the Better Value Option?
Integra LifeSciences Codman Arm Strong, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) progress within its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
Inogen's Solid Europe Business Shapes Q2, Prospects Bright
by Zacks Equity Research
Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.
Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid
by Zacks Equity Research
Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.
Boston Scientific to Expand Within PI Via VENITI Buyout
by Zacks Equity Research
Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.
Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now
by Zacks Equity Research
DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.
Zacks.com highlights: Turtle Beach, Integer Holdings and PCM
by Zacks Equity Research
Zacks.com highlights: Turtle Beach, Integer Holdings and PCM
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Ecolab (ECL) is likely to gain from a robust product portfolio, new product launches and expanding customer base.
Varian Acquires humediQ, Boosts Motion Management Portfolio
by Zacks Equity Research
Varian (VAR) incorporates humediQ's coveted IDENTIFY technology in its comprehensive suite of oncology solutions.
Allscripts Sunrise Picked by UK's Maidstone and Tunbridge Wells
by Zacks Equity Research
Allscripts' (MDRX) Sunrise platform witnesses a suite of developments, fortifying the company's global foothold.
OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE; declining segmental revenues raise concern.
Buy 3 Stocks With Rising Cash Flows to Scoop Up Big Gains
by Zacks Equity Research
Even though profit is a company's goal, cash is its lifeblood for existence and a measure of resiliency.
Allscripts Gains From Strong Results in Q2, Competition Rife
by Zacks Equity Research
Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.
Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance
by Zacks Equity Research
Inogen (INGN) puts up solid segmental show in Q2; international sales surge.
Zacks.com highlights: Turtle Beach, PetroChina, Harsco, Integer Holdings and Triton International
by Zacks Equity Research
Zacks.com highlights: Turtle Beach, PetroChina, Harsco, Integer Holdings and Triton International
5 Top Stocks With Striking Net Profit Margin
by Zacks Equity Research
Five stocks with handsome net profit margin that investors can count on for stellar returns.
Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid
by Zacks Equity Research
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.
Hill-Rom (HRC) Q3 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) registers a solid year-over-year revenue rise on strong domestic growth, driven by a robust performance at Patient Support Systems and Surgical Solutions.
ITGR vs. ABMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. ABMD: Which Stock Is the Better Value Option?
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
The improvement within Zimmer Biomet's (ZBH) global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging.
GNC Holdings (GNC) Q2 Earnings Beat, Revenues Miss Mark
by Zacks Equity Research
Though GNC Holdings' (GNC) domestic retail comps are slightly weaker than expected, the company performs strongly in e-commerce business and at International segment.
Baxter (BAX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Baxter (BAX) gains on the back of its core Renal Care segment in Q2; solid international sales encourage.
Zacks.com highlights: Hitachi, Integer Holdings, Panasonic and SunCoke Energy
by Zacks Equity Research
Zacks.com highlights: Hitachi, Integer Holdings, Panasonic and SunCoke Energy